Human granzyme B regulatory B cells prevent effector CD4+CD25- T cell proliferation through a mechanism dependent from lymphotoxin alpha

Front Immunol. 2023 Jul 31:14:1183714. doi: 10.3389/fimmu.2023.1183714. eCollection 2023.

Abstract

Introduction: Human Granzyme B (GZMB) regulatory B cells (Bregs) have suppressive properties on CD4+ effector T cells by a mechanism partially dependent on GZMB. Moreover, these cells may be easily induced in vitro making them interesting for cell therapy.

Methods: We characterized this population of in vitro induced GZMB+Bregs using single cell transcriptomics. To investigate their regulatory properties, Bregs or total B cells were also co-cultured with T cells and scRNAseq was used to identify receptor ligand interactions and to reveal gene expression changes in the T cells.

Results: We find that Bregs exhibit a unique set of 149 genes differentially expressed and which are implicated in proliferation, apoptosis, metabolism, and altered antigen presentation capacity consistent with their differentiated B cells profile. Notably, Bregs induced a strong inhibition of T cell genes associated to proliferation, activation, inflammation and apoptosis compared to total B cells. We identified and validated 5 receptor/ligand interactions between Bregs and T cells. Functional analysis using specific inhibitors was used to test their suppressive properties and we identified Lymphotoxin alpha (LTA) as a new and potent Breg ligand implicated in Breg suppressive properties.

Discussion: We report for the first time for a role of LTA in GZMB+Bregs as an enhancer of GZMB expression, and involved in the suppressive properties of GZMB+Bregs in human. The exact mechanism of LTA/GZMB function in this specific subset of Bregs remains to be determined.

Keywords: GZMB; LTA; regulation; regulatory B cell; single cell RNAseq; tolerance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes, Regulatory*
  • CD4-Positive T-Lymphocytes
  • Cell Proliferation
  • Granzymes
  • Humans
  • Ligands
  • Lymphotoxin-alpha*

Substances

  • Lymphotoxin-alpha
  • Granzymes
  • Ligands

Grants and funding

The authors declare that NS received funding from CEVA santé animale. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. This work was supported in the context of the LabEX IGO thanks to French government financial support managed by the National Research Agency via the “Investment into the Future” program (ANR-10-IBHU-005 and ANR-11- LABX-0016-01).